FDA approves the first #biosimilar for ustekinumab - However, not on the market until January 2025 given settlement between biosimilar developer Amgen & innovator J&J fiercepharma.com/pharma/amgen-s… #Biotech #IPSettlements #Biologics

Earlier this month, a virtual meeting of MPP's Governance Board was held. The Board members discussed👇🏽 ✅MPP's key achievements & progress made vis-a-vis our strategy ✅upcoming priorities, continuation of the expansion of MPP’s remit and how MPP could support diversified and

Glimpses of Day 2 at #GlobalBioIndia2023. It was an enriching day with friends from other TTOs, DBT-BIRAC leadership and Sathguru Management Consultants leadership and members. Looking forward to explore partnerships and collaboration today at booth no E199. Dr Shirshendu Mukherjee Vinita Jindal

📢 REGISTRATION NOW OPEN 📢 🚀 Livestream the launch of the #100DaysMission's third annual implementation report 🔗 Register here: wellcome-org.zoom.us/webinar/regist…

📢 SECOND PANEL ANNOUNCED! 📢 🌐 Hear this panel of distinguished global health experts discuss the realities of implementing the #100DaysMission for pandemic preparedness 🔗 Join the webinar on Weds Jan 24th: wellcome-org.zoom.us/webinar/regist…

Ophthalmology biosimilars continue to flavor of investments & transactions - Sandoz acquires ranibizumab #biosimilar from Coherus for USD 170 million & chooses to focus on bigger space in oncology fiercepharma.com/pharma/coherus…

Re-emerging infectious diseases are a looming threat. Several lessons from measles outbreaks gripping high income countries. gov.uk/government/new…

Licensing & tech transfer as drivers of growth, equitable access & operational transformation. Join us in Bangalore to ideate with cross-section of academia, industry, Government and multilateral organizations #IPlicensing #IntellectualProperty #TechTransfer

Our focus on preparedness cannot wane in 2024. Collective commitment will be key to realizing the 100DM goal of access to diagnostics, therapeutics and vaccines in an equitable manner. Are you joining online today?

🚀#HappeningNow in #Rome at International Pandemic Preparedness Secretariat #100DaysMissionreport launch – Panel on 100 Days Mission: In Practice 👇🏽 🗣️Pushpa Vijayaraghavan, MPP Board Member, highlights MPP’s contribution to the report, especially on the development of the #Therapeutics roadmap, based on MPP’s

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND "Recognising the cross-cutting nature of pandemic preparedness is essential. We must respond to present challenges & prepare for the future crises that may come through war, famine, & climate change" - Dr Mona Nemer, Chief Science Advisor of Canada Dr. Mona Nemer

Listening to MPP Board Member Pushpa Vijayaraghavan at the #100DM report launch “The words I want to leave behind are ‘equitable access at scale’” Well said - how we achieve that must be the red thread of this vital #100DM effort International Pandemic Preparedness Secretariat Pandemic Action Network

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND Dr. Mona Nemer CEPI Samia Saad Unitaid Dr Philippe Duneton "The single biggest challenge is incentivising manufacturers. If we're going to respond rapidly, we need licencing, manufacturing capacity & prior approval” Pushpa Vijayaraghavan, Director & Practice Lead, Healthcare & Innovation Advisory, at Sathguru Management Consultants

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND Dr. Mona Nemer CEPI Samia Saad Unitaid Dr Philippe Duneton Pushpa Vijayaraghavan "The idea of increasing convergence is very important for the future. A good response will only come if we prepare. We need to advance MCMs as much as we can and think about the finish line" Dr Marco Cavaleri, Head of Office, Health Threats & vaccines strategy, EMA

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND Dr. Mona Nemer CEPI Samia Saad Unitaid Dr Philippe Duneton Pushpa Vijayaraghavan EU Medicines Agency "Strong health systems, resilient workforce & strengthened national R&D capabilities will enable us to respond within 100 days & get MCMs where they're most needed" Shingai Machingaidze, Ag Chief Science Officer, Africa CDC; #100DM Science & Technology Expert Group Co-Chair

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND Dr. Mona Nemer CEPI Samia Saad Unitaid Dr Philippe Duneton Pushpa Vijayaraghavan EU Medicines Agency Africa CDC Pandemic Action Network Aggrey Aluso "There must be collective responsibility & national ownership of the #100DM framework to see success. Govts need to prioritise R&D & earmark budgets for pandemic preparedness" Dr Renu Swarup, Former Secretary, Dept of Biotechnology, Ministry of Science & Technology, Govt of India

Jeremy Farrar World Health Organization (WHO) Victor Dzau National Academy of Medicine University of Oxford The Lambe Lab Instituto Todos pela Saúde (ITpS) FIND Dr. Mona Nemer CEPI Samia Saad Unitaid Dr Philippe Duneton Pushpa Vijayaraghavan EU Medicines Agency Africa CDC Pandemic Action Network Aggrey Aluso IFPMA Natural History Museum "Partnership has to happen at the national, regional and global levels. We must overcome siloes and create people-centric-systems to deliver pandemic preparedness" Dr Mona Nemer, Chief Science Advisor of Canada & 100DM Steering Group Chair, closes our panel event

What started as a quest for health security, is rapidly evolving into expanding private sector opportunity to participate in the $28Bn African pharma market. Whats your strategy for Africa? Join me on the CPHI webinar tomorrow. #PharmaMarket #VaccineManufacturing #Preparedness

A long and windy path to market - decade after our efforts to license an omalizumab biosimilar, the first ones make it to market. Celltrion gets EMA marketing authorization for #biosimilar for Xolair businesskorea.co.kr/news/articleVi…

#Biosimilars commercial momentum gets a boost - hashtag#USFDA reduces data requirement for hashtag#interchangeability designation. Our blog post on this significant development and implications for industry. lnkd.in/dahF9-wX #biopharma #Pharma #Biotech #Regulations